1-9 of 9
Ruth Mary De Tute
Close
Sort by
Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 835.
https://doi.org/10.1182/blood.V130.Suppl_1.835.835
Published: 2017
Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Rakesh Popat, MD PhD, Ruth Mary De Tute, BSc,MSc, Nicholas Counsell, Dunnya De-Silva, Beth Phillips, MBBS, FRCPath, BSc, James D Cavenagh, Toyin Adedayo, Nivette Braganza, Claire Roddie, PhD MD, Mathew Streetly, Stephen Schey, MBBS, Mickey Koh, MD PhD, Josephine Crowe, Michael F. Quinn, FRCPath, MB, MD MRCP, Shirley D'Sa, MD FRCP, FRCPath, Andres E. Virchis, FRCP, FRCPath, Gordon Cook, PhD, Charles R Crawley, Guy Pratt, MD FRCP, FRCPath, Mark Cook, MBChB,PhD, Paul Smith, Laura Clifton-Hadley, PhDBSc, Neil Rabin, Roger G Owen, MD, Kwee Yong, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1864.
https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864
Published: 2017
Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD
Journal: Blood
Blood (2016) 128 (22): 245.
https://doi.org/10.1182/blood.V128.22.245.245
Published: 2016
Journal Articles

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

Andy C Rawstron, BSc, PhD, Dena Howard, Lucy McParland, Ruth Mary de Tute, PhD FRCPath, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, PhD, Rebecca Bishop, BSc, Francesca J Yates, PhD MSci, Kristian Brock, MSc, BSc, Samuel Muñoz-Vicente, Peter Hillmen
Journal: Blood
Blood (2016) 128 (22): 3226.
https://doi.org/10.1182/blood.V128.22.3226.3226
Published: 2016
Journal Articles

Validation of Plasma Cell Immunophenotype As a Biomarker to Identify High-Risk Smoldering Myeloma

Andy C Rawstron, BSc, PhD, Alex Smith, Ruth Mary de Tute, PhD FRCPath, Dan Painter, Eve Roman, Roger G Owen, MD
Journal: Blood
Blood (2016) 128 (22): 4451.
https://doi.org/10.1182/blood.V128.22.4451.4451
Published: 2016
Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong
Journal: Blood
Blood (2016) 128 (22): 4508.
https://doi.org/10.1182/blood.V128.22.4508.4508
Published: 2016
Journal Articles

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Andy C Rawstron, BSc, PhD, Talha Munir, Samuel Muñoz-Vicente, Kristian Brock, MSc, BSc, Francesca J Yates, PhD MSci, Rebecca Bishop, BSc, Surita Dalal, Ruth Mary de Tute, PhD FRCPath, Adrian Bloor, Oonagh M Sheehy, MB BSc FRCP FRCPAth, Andrew R. Pettitt, Christopher P Fox, MBChB, MRCP, FRCPath, Christopher Fegan, Stephen Devereux, PhD FRCP, FRCPath, Donald Macdonald, Peter Hillmen
Journal: Blood
Blood (2016) 128 (22): 2049.
https://doi.org/10.1182/blood.V128.22.2049.2049
Published: 2016
Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB
Journal: Blood
Blood (2015) 126 (23): 2669.
https://doi.org/10.1182/blood.V126.23.2669.2669
Published: 2015
Journal Articles

The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring

Andy C Rawstron, Dena Cohen, Ruth Mary De Tute, Lucy McParland, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, Peter Hillmen
Journal: Blood
Blood (2015) 126 (23): 1717.
https://doi.org/10.1182/blood.V126.23.1717.1717
Published: 2015